Cell line derived xenograft (CDX) models offer key decision-making information that allows the therapeutic candidates to move forward in preclinical testing for cancer immunotherapy development. To improve the cost-effectiveness and timeliness of sponsored preclinical development projects, Creative Biolabs has established multiple in vivo analysis systems with various CDX models to evaluate the candidates’ mechanism of action, PD/PK profiles.
Well characterized cell line derived xenografts cover the following types for your research:
Creative Biolabs has established over 200 validated and well-characterized CDX models as well as luciferase-labeled CDX models, which ensures an easy model selection. CDX models cover the following cancer types, but not limited to these. Working with CBL gives you access to customized CDX models to fit your program.
■ Brain Cancer | ■ Brest Cancer | ■ Bone Cancer | ■ Bladder Cancer | ■ Cervical Carcinoma |
■ Colorectal Cancer | ■ Endometrium Cancer | ■ Epidermoid Carcinoma | ■ Gallbladder carcinoma | ■ Gastric Carcinoma |
■ Glioma | ■ Head and neck Cancer | ■ Liver Cancer | ■ Lung Cancer | ■ Melanoma |
■ Mesothelioma | ■ Nasopharyngeal Carcinoma | ■ Neuroblastoma | ■ Ovarian Cancer | ■ Pancreatic Cancer |
■ Prostate Cancer | ■ Renal Carcinoma | ■ Rhabdomyosarcoma | ■ Sarcoma | ■ Skin Cancer |
■ Thyroid Cancer | ■ Uterine | ■ Vulva Cancer |
■ Acute Lymphoblastic Leukemia | ■ Acute Monocytic Leukemia | ■ Acute Myeloid Leukemia | ■ Acute Myeloblastic Leukemia |
■ Acute Promyelocytic Leukemia | ■ Chronic Myeloid Leukemia | ■ Eosinophilic Leukemia | ■ Erythro Leukemia |
■ Histiocytic Lymphoma | ■ Megakaryoblastic Leukemia | ■ Multiple Myeloma | ■ Non-Hodgkin Lymphoma |
■ Lymphoma (B-cell) |
Our portfolio of CDX models are evaluated on a regular basis for response to standards of care which are available for combination studies design.
If you need to build or order customized CDX model, please don’t hesitate to contact us.
Reference
For Research Use Only | Not For Clinical Use